|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Prodromal Parkinson’s disease: hype or hope for disease-modification trials?显示文摘The ultimate goal in Parkinson’s disease (PD) research remains the identification of treatments that are capable of slowing or even halting the progression of the disease. The failure of numerous past disease-modification trials in PD has been attributed to a variety of factors related not only to choosing wrong interventions, but also to using inadequate trial designs and target populations. In patients with clinically established PD, neuronal pathology may already have advanced too far to be modified by any intervention. Based on such reasoning, individuals in yet prediagnostic or prodromal disease stages, may provide a window of opportunity to test disease-modifying strategies. There is now sufficient evidence from prospective studies to define diagnostic criteria for prodromal PD and several approaches have been studied in observational cohorts. These include the use of PD-risk algorithms derived from multiple established risk factors for disease as well as follow-up of cohorts with single defined prodromal markers like hyposmia, rapid eye movement sleep behavior disorders, or PD gene carriers. In this review, we discuss recruitment strategies for disease-modification trials in various prodromal PD cohorts, as well as potential trial designs, required trial durations, and estimated sample sizes. We offer a concluding outlook on how the goal of implementing disease-modification trials in prodromal cohorts might be achieved in the future. | Philipp Mahlknecht Kathrin Marini Mario Werkmann Werner Poewe Klaus Seppi | 2022 | Translational Neurodegeneration2022，11，1： | 2 |
| 2 | Osteoprotegerin Is a Risk Factor for Progressive Atherosclerosis and Cardiovascular Disease显示文摘 | Stefan Kiechl Georg Schett Gregor Wenning Kurt Redlich Martin Oberhollenzer Agnes Mayr Peter Santer Josef Smolen Werner Poewe Johann Willeit | 2004 | Circulation: Journal of the American Heart Association2004，，18： | 2 |
| 3 | Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson’s disease – Clinical practice recommendations显示文摘 | Claudia Trenkwalder K. Ray Chaudhuri Pedro J. García Ruiz Peter LeWitt Regina Katzenschlager Friederike Sixel-D?ring Tove Henriksen ángel Sesar Werner Poewe Mary Baker Andres Ceballos-Baumann Günther Deuschl Sophie Drapier Georg Ebersbach Andrew Evans Hub | 2015 | Parkinsonism and Related Disorders2015，，9： | 1 |
| 4 | Progression of brain atrophy in multiple system atrophy显示文摘 | Christian Brenneis Karl Egger Christoph Scherfler Klaus Seppi Michael Schocke Werner Poewe Gregor K. Wenning | 2007 | Journal of Neurology2007，，2： | 1 |
| 5 | Levodopa in the treatment of Parkinson's disease: an old drug still going strong 显示文摘 | Werner Poewe Angelo Antonini Jan CM Zijlmans | 2010 | Clin Interv Aging2010，5，： | 1 |
| 6 | Riluzole in Huntington’s disease (HD): an open label study with one year follow up显示文摘 | Klaus Seppi Joerg Mueller Thomas Bodner Elisabeth Brandauer Thomas Benke Helga Weirich-Schwaiger Werner Poewe Gregor K. Wenning | 2001 | Journal of Neurology2001，，10： | 1 |
| 7 | Treatments for Parkinson disease - past achievements and current clinical needs显示文摘 | Werner Poewe | 2009 | Neurology2009，72，2： | 1 |
| 8 | Multiple system atrophy显示文摘 | Gregor K Wenning Carlo Colosimo Felix Geser Werner Poewe | 2004 | Lancet Neurology2004，，： | 1 |
| 9 | Chronic Infections and the Risk of Carotid Atherosclerosis: Prospective Results From a Large Population Study显示文摘 | Stefan Kiechl Georg Egger Manuel Mayr Christian J. Wiedermann Enzo Bonora Friedrich Oberhollenzer Michele Muggeo Qingbo Xu Georg Wick Werner Poewe Johann Willeit | 2001 | Circulation: Journal of the American Heart Association2001，，8： | 1 |
| 10 | 左旋多巴的临床应用(下)显示文摘目前人们普遍认识到左旋多巴明显改善了帕金森病运动不能的进展和病死率,但在对左旋多巴抵抗的不典型帕金森综合征患者中无此结果。Hoehn比较了左旋多巴出现前后每5年间的病死率和致残率(Hoehn&Yahr评分Ⅳ和Ⅴ级)的差异,结果发现,左旋多巴减少同期患者运动不能的发生率多达50%。然而,在治疗和未治疗的患者间,疾病的进展差异无显著性。该结果表明左旋多巴并不阻止帕金森病的进展。此外,左旋多巴不能影响肢体受累的模式,包括从一侧上肢或下肢随时间进展累及到对侧或其他肢体。 | Gregor K.Wenning Werner Poewe 苏雅茹 蒋雨平 | 2005 | 中华医学信息导报2005，20，19： | 1 |
| 11 | Body Iron Stores and the Risk of Carotid Atherosclerosis: Prospective Results From the Bruneck Study显示文摘 | Stefan Kiechl Johann Willeit Georg Egger Werner Poewe Friedrich Oberhollenzer | 1997 | Circulation1997，，10： | 1 |
| 12 | Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson’s disease: a double-blind, double-dummy, randomised controlled trial显示文摘 | Werner H Poewe Olivier Rascol Niall Quinn Eduardo Tolosa Wolfgang H Oertel Emilia Martignoni Markus Rupp Babak Boroojerdi | 2007 | Lancet Neurology2007，，： | 1 |
| 13 | 左旋多巴的临床应用(上)显示文摘1961年,Birkmayer等发现左旋多巴具有抗帕金森病作用,这是帕金森病药物治疗电上的革命性创举。左旋多巴干1973年上市,临床应用已达30年。最初人们乐观地认为左旋多巴能逆转帕金森病,但大多数患者在左旋多巴长期治疗后急剧出现左旋多巴引起的异动症及运动反应性波动。此外,目前已明确,左旋多巴并不能阻止随疾病加重而出现的某些症状(如步态异常、失平衡和言语、吞咽困难)的进展。最近研究认为左旋多巴毒性会影响残存的DA(多巴胺能)神经无的存活和功能。 | Gregor K.Wenning Werner Poewe 苏雅茹 蒋雨平 | 2005 | 中华医学信息导报2005，20，19： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员